Virta has turned its expertise in health coaching and nutrition services to reduce Americans' reliance on GLP-1 medications. The company operates a performance-based model where they charge enterprise partners for services but put 100% of their fees at risk—only getting paid if they achieve successful outcomes. This dual positioning—reversing type 2 diabetes while expanding into obesity management—positions Virta as a cost-reduction alternative to expensive pharmaceutical interventions.
Cyborg Score Rationale
Among enrolled patients in its clinical trial at one year, 60% achieved diabetes reversal, and 94% of insulin users reduced or eliminated usage altogether. The company has raised $807M in funding (as of February 2026) and works with 550 organizations, covering 12 million Americans. Strong clinical data, proven ROI model, and enterprise scale provide solid fundamentals, though private status limits exit optionality.
Top Insights
The high cost of breakthrough weight-loss drugs (upwards of $15,000 a year) is giving Virta Health a huge second wind as the company taps into cost concerns among corporations paying employee medication bills.
94% of patients using insulin decrease or eliminate their dosage at one year, with 63% of all prescriptions eliminated at one year.
The company, founded in 2014, has twice made CNBC's Disruptor 50 for its novel approach to diabetes disease management.
Virta Health has revenues estimated between $250–500 million and has raised over $800 million in funding.
Named Competitors
Omada Health — Digital therapeutics for chronic disease management
Teladoc Health — Virtual care and remote patient monitoring platform
Glooko — Diabetes management and glucose data platform
Canary Health — Digital therapeutics for metabolic disease
Recent Developments
(June 2025) Named to CNBC Disruptor 50 list for second time